Search Results
Search for other papers by Ayse Nurcan Cebeci in
Google Scholar
PubMed
Search for other papers by Vera Schempp in
Google Scholar
PubMed
Search for other papers by Katharina Förtsch in
Google Scholar
PubMed
Search for other papers by Bettina Gohlke in
Google Scholar
PubMed
Search for other papers by Michaela Marx in
Google Scholar
PubMed
Search for other papers by Helmuth-Guenther Dörr in
Google Scholar
PubMed
Search for other papers by Joachim Woelfle in
Google Scholar
PubMed
While subclinical or overt hypothyroidism are common in Down syndrome (DS); Graves’ disease (GD) is rare (ranges 0.6–3%). We aimed to evaluate the clinical features, course, and treatment of GD in children with DS and compare them with those without DS. Among 161 children with GD, 13 (8 female, 5 male) had DS (8%). Data were collected retrospectively from patients’ medical records. The mean age at diagnosis was 10.6 ± 4.5 years, with a female-to-male ratio 1.6:1. The main symptoms were weight loss (n = 6), increased irritability (n = 3), and increased sweating (n = 3). None had orbitopathy. Seven of 11 patients with a thyroid ultrasound at diagnosis had a goitre. On admission, all had thyroid-stimulating hormone (TSH) <0.01 mU/L (normal range (NR): 0.51–4.30), free triiodothyronine, free thyroxine (mean ± s.d .), and thyrotrophin receptor antibodies (median, range) were 22.2 ± 10.2 pmol/L (NR: 3.5–8.1), 50.2 ± 18.7 pmol/L (NR 12.6–20.9), and 17.0 (2.89–159.0) U/L (NR <1), respectively. Patients were treated either with methimazole (n = 10) or carbimazole (n = 3), a dose of 0.54 ± 0.36 mg/kg/day. The treatment was ‘block and replace’ in ten patients and ‘dose titration’ in three patients, with a mean duration of 43.4 ± 11.0 months. Of 13 patients, four are still receiving primary treatment, three are in remission, one patient had two medically treated recurrences, three underwent surgery without complications, and two patients were lost to follow-up. Our data show that the clinical course of GD in patients with DS was similar to those without DS and suggest that a prolonged medical therapy should be the preferred option.
Department of Pediatric Endocrinology, Wilhelmina Children’s Hospital/ University Medical Center Utrecht, Utrecht, The Netherlands
Search for other papers by S C Clement in
Google Scholar
PubMed
Search for other papers by W E Visser in
Google Scholar
PubMed
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Search for other papers by C A Lebbink in
Google Scholar
PubMed
Search for other papers by D Albano in
Google Scholar
PubMed
Search for other papers by H L Claahsen-van der Grinten in
Google Scholar
PubMed
Search for other papers by A Czarniecka in
Google Scholar
PubMed
Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
Search for other papers by R P Dias in
Google Scholar
PubMed
Search for other papers by M P Dierselhuis in
Google Scholar
PubMed
Search for other papers by I Dzivite-Krisane in
Google Scholar
PubMed
Search for other papers by R Elisei in
Google Scholar
PubMed
Search for other papers by A Garcia-Burillo in
Google Scholar
PubMed
Search for other papers by L Izatt in
Google Scholar
PubMed
Search for other papers by C Kanaka-Gantenbein in
Google Scholar
PubMed
Search for other papers by H Krude in
Google Scholar
PubMed
Search for other papers by L Lamartina in
Google Scholar
PubMed
Search for other papers by K Lorenz in
Google Scholar
PubMed
Search for other papers by M Luster in
Google Scholar
PubMed
Search for other papers by R Navardauskaitė in
Google Scholar
PubMed
Search for other papers by M Negre Busó in
Google Scholar
PubMed
Search for other papers by K Newbold in
Google Scholar
PubMed
Search for other papers by R P Peeters in
Google Scholar
PubMed
Search for other papers by G Pellegriti in
Google Scholar
PubMed
Search for other papers by A Piccardo in
Google Scholar
PubMed
Search for other papers by A L Priego in
Google Scholar
PubMed
Search for other papers by A Redlich in
Google Scholar
PubMed
Search for other papers by L de Sanctis in
Google Scholar
PubMed
Search for other papers by M Sobrinho-Simões in
Google Scholar
PubMed
Search for other papers by A S P van Trotsenburg in
Google Scholar
PubMed
Search for other papers by F A Verburg in
Google Scholar
PubMed
Search for other papers by M Vriens in
Google Scholar
PubMed
Search for other papers by T P Links in
Google Scholar
PubMed
Developmental Endocrinology Research Group, Royal Hospital for Children, University of Glasgow, Glasgow, UK
Office for Rare Conditions, University of Glasgow, Glasgow, UK
Search for other papers by S F Ahmed in
Google Scholar
PubMed
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Search for other papers by H M van Santen in
Google Scholar
PubMed
Union’s Health Programme (2014–2020) on the EuRRECa project ‘777215/EuRRECa’ and the EuRR-Bone project ‘946831/EuRR-Bone’. The EuRRECa project is also grateful to the European Society of Endocrinology and the European Society for Paediatric Endocrinology